John Philip Tabb

John Philip Tabb

Auto-generated profile, based on publicly available information

John Philip Tabb

Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, MI, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2022 in Neuro-Oncology Advances
Verified
Journal Article
Open access
PDF file
KUKutluay Uluc
Kutluay Uluc
PAPrakash Ambady
Prakash Ambady
MMMatthew K McIntyre
Matthew K McIntyre
JTJohn Philip Tabb
John Philip Tabb
CKCymon N Kersch
Cymon N Kersch
ENEdward A Neuwelt
Edward A Neuwelt
Intra-arterial administration of chemotherapy with or without osmotic blood–brain barrier disruption enhances delivery of therapeutic agents to brain tumors. The aim of this study is to evaluate the safety of these procedures. Retrospectively collected data from a prospective database of consecutive patients with primary and metastatic brain tumors who received intra-arterial chemotherapy without osmotic blood–brain barrier disruption (IA) or intra-arterial chemotherapy with osmotic blood–brain barrier disruption (IA/OBBBD) at Oregon Health and Science University (OHSU) between December 1997 and November 2018 is reported. Chemotherapy-related complications are detailed per Common Terminology Criteria for Adverse Events (CTCAE) guidelines. Procedure-related complications are grouped as major and minor. 4939 procedures (1102 IA; 3837 IA/OBBBD) were performed on 436 patients with various pathologies (primary central nervous system lymphoma [26.4%], glioblastoma [18.1%], and oligodendroglioma [14.7%]). Major procedure-related complications (IA: 12, 1%; IA/OBBBD: 27, 0.7%; P = .292) occurred in 39 procedures including 3 arterial dissections requiring intervention, 21 symptomatic strokes, 3 myocardial infarctions, 6 cervical cord injuries, and 6 deaths within 3 days. Minor procedure-related complications occurred in 330 procedures (IA: 41, 3.7%; IA/OBBBD: 289, 7.5%; P = .001). Chemotherapy-related complications with a CTCAE attribution and grade higher than 3 was seen in 359 (82.3%) patients. We provide safety and tolerability data from the largest cohort of consecutive patients who received IA or IA/OBBBD. Our data demonstrate that IA or IA/OBBBD safely enhance drug delivery to brain tumors and brain around the tumor.

1 October 2026 in Foot & Ankle Orthopaedics
Verified
Journal Article
Open access
ESElinor A. Stern
Elinor A. Stern
SSSanidhya Singh
Sanidhya Singh
MFMichael Fernandes
Michael Fernandes
BSBarrie Sugarman
Barrie Sugarman
ITIan Torchia
Ian Torchia
PTPaul Talusan
Paul Talusan
Background: Operative management of Insertional Achilles tendinopathy (IAT) involves debridement and resection of the Haglund deformity. Open approaches are effective but large incisions carry risks such as wound complications and lengthy recovery times. Minimally invasive (MIS) techniques have been developed; however, literature is limited regarding outcomes of MIS techniques. This study compares patient-reported outcome measures for patients undergoing open vs MIS Achilles debridement and Haglund resection. Methods: Patients 18 years of age or older undergoing open or MIS Achilles debridement and Haglund resections by 3 fellowship-trained foot and ankle surgeons at a single institution were identified from January 2018 to December 2025. Demographic data as well as preoperative and postoperative patient-reported outcome (Patient-Reported Outcomes Measurement Information System [PROMIS] physical function and pain interference) scores for function and pain were collected and compared between MIS and open groups. Results: Twenty-three patients in the MIS group and 49 patients (undergoing 50 surgeries) in the open group were included. With the numbers available, no significant difference in preoperative PROMIS physical function ( P = .877) or pain interference ( P = .747) scores could be detected between groups. Postoperatively, PROMIS physical function scores at 6 weeks were higher for patients in the MIS group (34.4 vs 28.5, P = .013). With the numbers available, no significant difference in PROMIS pain interference scores could be detected between groups at any postoperative time point (all P ≥ .144). There were zero postoperative infections in the MIS group (0/23) and 5 postoperative infections in the open group (5/50) ( P = .173). There were zero postoperative Achilles tendon ruptures in the MIS group (0/23) and 2 postoperative ruptures in the open group (2/50; P > .99). Conclusion: With the numbers available, no significant difference in postoperative patient-reported outcomes could be detected between MIS Achilles debridement and Haglund resection and standard open approaches at most time points. At 6 weeks postoperatively, patients who had undergone MIS surgery reported better functional outcomes; however, no significant difference in outcomes could be detected at any other time point. No postoperative Achilles ruptures or infections were noted in the MIS group. MIS approaches to treatment for IAT may be a viable alternative to classic open approaches, although the small sample and retrospective design limit this conclusion. Level of Evidence: Level III, retrospective comparitive study.